Published in final edited form as:

Hum Mutat. 2017 October ; 38(10): 1412–1420. doi:10.1002/humu.23287.

Compound Heterozygosity for Loss-of-Function *GARS* Variants Results in a Multi-System Developmental Syndrome that Includes Severe Growth Retardation

Stephanie N. Oprescu¹, Xenia Chepa-Lotrea², Ryuichi Takase³, Gretchen Golas², Thomas C. Markello², David R. Adams², Camilo Toro², Andrea L. Gropman⁴, Ya-Ming Hou³, May Christine V. Malicdan², William A. Gahl², Cynthia J. Tifft², and Anthony Antonellis^{1,5,*}

¹Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, USA

²NIH Undiagnosed Diseases Program and Office of the Clinical Director, National Human Genome Research Institute, National Institutes of Health

³Department of Biochemistry and Molecular Biochemistry, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

⁴Division of Neurogenetics and Developmental Pediatrics, Children's National Medical Center, Washington, District of Columbia, USA

⁵Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA

Abstract

Aminoacyl-tRNA synthetases (ARSs) are ubiquitously expressed enzymes that ligate amino acids onto tRNA molecules. Genes encoding ARSs have been implicated in myriad dominant and recessive disease phenotypes. Glycyl-tRNA synthetase (*GARS*) is a bi-functional ARS that charges tRNA^{Gly} in the cytoplasm and mitochondria. *GARS* variants have been associated with dominant Charcot-Marie-Tooth disease but have not been convincingly implicated in recessive phenotypes. Here we describe a patient from the NIH Undiagnosed Diseases Program with a multi-system, developmental phenotype. Whole-exome sequence analysis revealed that the patient is compound heterozygous for one frameshift (p.Glu83Ilefs*6) and one missense (p.Arg310Gln) *GARS* variant. Using *in vitro* and *in vivo* functional studies, we show that both *GARS* variants cause a loss-of-function effect: the frameshift variant results in depleted protein levels and the missense variant reduces *GARS* tRNA charging activity. In support of *GARS* variant pathogenicity, our patient shows striking phenotypic overlap with other patients having ARS-related recessive diseases, including features associated with variants in both cytoplasmic and mitochondrial ARSs; this observation is consistent with the essential function of *GARS* in both cellular locations. In summary, our clinical, genetic, and functional analyses expand the phenotypic spectrum associated with *GARS* variants.

*To whom correspondence can be addressed at: Anthony Antonellis, University of Michigan Medical School, 3710A Medical Sciences II, 1241 E. Catherine St. SPC 5618, Ann Arbor, MI, antonell@umich.edu.

Keywords

Glycyl-tRNA synthetase; *GARS*; aminoacyl-tRNA synthetase; growth retardation; developmental syndrome

INTRODUCTION

Aminoacyl-tRNA synthetases (ARS) are ubiquitously expressed, essential enzymes that charge tRNA molecules with cognate amino acids—the first step of cytoplasmic and mitochondrial protein synthesis. The human nuclear genome harbors 37 ARS genes including 17 that encode a cytoplasmic enzyme, 17 that encode a mitochondrial enzyme, and three that encode bi-functional enzymes that charge tRNA for protein synthesis in both cellular locations (Antonellis and Green, 2008). ARS loci and enzymes are named by the single-letter code for the amino acid that they charge, plus ‘ARS’ and a variable ‘2’ for enzymes that charge tRNA exclusively in the mitochondria. For example, *AARS* encodes cytoplasmic alanyl-tRNA synthetase and *AARS2* encodes the mitochondrial form of alanyl-tRNA synthetase.

Glycyl-tRNA synthetase (*GARS*; MIM# 600287) encodes a bi-functional tRNA-charging enzyme that differentially localizes to the cytoplasm or mitochondria via two translation start sites that either include or exclude a mitochondrial targeting sequence (Antonellis and Green, 2008). *GARS* variants have been implicated in CMT2D, an autosomal dominant, axonal form of Charcot-Marie-Tooth disease (MIM# 600287) (Antonellis et al., 2003). CMT2D is characterized by an upper limb predominant peripheral neuropathy that affects motor and sensory function in the distal extremities (Sivakumar et al., 2005). One patient with a recessive mitochondrial phenotype was reported to be compound heterozygous for *GARS* missense variants: p.Arg596Gln and p.Ser635Leu (McMillan et al., 2014). However, certain limitations of the above study indicated that additional analyses were required to determine the role of *GARS* variants in recessive disease. First, the restriction of the phenotype to impaired mitochondrial function is surprising given the role of *GARS* in cytoplasmic protein translation and the severity of fly and mouse phenotypes associated with bi-allelic mutations in glycyl-tRNA synthetase upon severe depletion of *GARS* function (Chihara et al., 2007; Motley et al., 2011). Second, the authors of the above study did not provide functional data supporting the pathogenicity of the variants; enzyme kinetic analyses were not performed and, indeed, p.Ser635Leu was previously shown to encode a functional *GARS* enzyme (Nangle et al., 2007). Finally, p.Ser635Leu was previously shown to not be associated with dominant human disease (Griffin et al., 2014); however, the variant was not evaluated for a role in recessive phenotypes. Here we present clinical, genetic, and functional data that implicate compound heterozygosity for loss-of-function *GARS* variants in a recessive, early onset, multi-system, developmental phenotype. Our findings expand the phenotypic heterogeneity associated with *GARS* variants.

MATERIAL AND METHODS

Clinical evaluation and variant analysis

The proband was admitted to the National Institutes of Health (NIH) Undiagnosed Diseases Program (UDP) under the protocol 76-HG-0238, “Diagnosis and Treatment of Patients with Inborn Errors of Metabolism or Other Genetic Disorders,” approved by the National Human Genome Research Institute (NHGRI) Institutional Review Board (IRB). Clinical data were obtained after written informed consent from the proband’s parents. Genomic DNA was extracted from whole blood using the Gentra Puregene Blood Kit (Qiagen). Single-nucleotide polymorphism (SNP) analyses were performed using an Illumina Omni Express 12 (hg18) SNP array and the Genome Studio software program. Whole-exome sequencing was performed using the Illumina HiSeq2000 platform and the TrueSeq capture kit (Illumina) by the NIH Intramural Sequencing Center (NISC) as described (Bentley et al., 2008; Gnirke et al., 2009; Teer et al., 2010; Gahl et al., 2012). Sequence data were aligned to the human reference genome (hg19) using Novoalign (Novocraft Technologies). Variants were analyzed, sorted, and filtered with VarSifter and a graphical java tool to view, sort, and filter variants (Teer et al., 2012). Variants were filtered based on allele frequencies in the NIH-UDP (Gahl and Tift, 2011; Gahl et al., 2012; Markello et al., 2012) cohort (<0.06). Variant annotation is based on NM_002047.3 and each variant was submitted to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>): c.246_249del is accession number SCV000579486, and c.929G>A is accession number SCV000579487.

Protein isolation and western blot analysis

Primary fibroblasts from the affected individual and a control individual (*i.e.*, bearing no *GARS* variants) were obtained and utilized for western blot analysis. Cells were cultured in T-75cm³ treated cell culture flasks (USA Scientific) and maintained at 37°C and 5% CO₂ in complete medium [Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen) with 10% fetal bovine serum (FBS; ThermoFisher Scientific), 1X L-glutamine (Corning), 1X Penicillin-Streptomycin (final concentration 50units/mL penicillin and 50µg/mL streptomycin; ThermoFisher Scientific)]. Cells were harvested at 90% confluence with 3mL .25% trypsin (ThermoFisher Scientific), quenched with 7mL complete cell medium, and collected at 2,000 rpm for 2 minutes. The resulting pellet was resuspended in 1mL cell lysis buffer [RIPA buffer (ThermoFisher Scientific) + 1X EDTA-free protease inhibitor (ThermoFisher Scientific)] and incubated at 4°C for 30 minutes with gentle shaking. Cell debris was collected at 4°C and 12,000 rpm for 5 minutes and the resulting supernatant was subjected to western blot analysis.

Total protein concentration was measured using the Thermo Scientific Pierce BCA Protein Assay Kit (ThermoFisher Scientific) and 10µg protein/sample was analyzed unless otherwise specified. Protein samples were prepared in 1X SDS-sample buffer (ThermoFisher Scientific) and 1µL 2-mercaptoethanol (BME), denatured at 99°C for 5 minutes and separated on a pre-cast 4–20% tris-glycine protein gel (ThermoFisher Scientific) at 150 V for 2 hours at room temperature. Prior to protein transfer, a polyvinylidene difluoride (PVDF) membrane was pre-washed in 100% methanol and soaked in 1X transfer buffer (ThermoFisher Scientific) with extra thick blot paper (Bio Rad) and 3 mm Chromatography

paper (Whatman PLC). Protein was transferred onto the membrane using a Transbot-SD Semi-Dry Transfer Cell (Bio Rad) at 23V for 1.5 hours at room temperature and subsequently blocked over night at 4°C in blocking solution [1 g dry milk powder, 50 mL 1X TBST (tris-buffered saline solution and tween 20, pH 7.5)]. The membrane was cut in half and incubated in blocking solution with either anti-GARS⁶⁷³ antibody (Antonellis et al., 2006) (at 1/2,000 dilution) or anti-actin antibody [at 1/5,000 dilution (Sigma Aldrich)] at room temperature for 1 hour. The membrane was washed three times in 1X TBST to remove unbound primary antibody and incubated in blocking solution with 10 ng/mL Donkey anti-Rabbit IgG HRP secondary antibody (ThermoFisher Scientific) at room temperature for 1 hour. The membrane was washed three times in 1X TBST to remove unbound secondary antibody and exposed using SuperSignal West Dura substrate and enhancer (ThermoFisher Scientific). Western blot analysis was repeated four independent times with independent fibroblast cell lysates and ImageJ (<https://imagej.nih.gov/ij/>) was used to quantify band intensity. The analyzed control and affected fibroblast cell lines were passage-matched (± 3 passages).

Generation of GARS expression constructs

GARS expression constructs were generated using Gateway cloning technology (Invitrogen). The human *GARS* open-reading frame was amplified from human cDNA using primers designed with Gateway sequences attB1 (forward) and attB2 (reverse; primer sequences available on request). Entry clones were generated by recombining PCR-purified amplicons into the pDONR221 vector using BP clonase. After transformation into *E. coli*, DNA from individual entry clones was isolated and subjected to Sanger sequencing analysis to confirm the presence of the appropriate wild-type gene. Oligonucleotides containing sequences corresponding to the c.929G>A *GARS* variant (encoding p.Arg310Gln) were generated and mutagenesis was performed using the QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene). After transformation into *E. coli*, DNA from individual clones was purified and sequenced to confirm the presence of each variant and the absence of any errors. Validated entry clones were purified and recombined into a Gateway-compatible pET-21a(+) vector for aminoacylation assays (Griffin et al., 2014) using LR clonase. DNA from the resulting expression constructs was purified and digested with *Bst*GI (New England Biosystems) to confirm the presence of the insert.

For yeast complementation assays, human GARS proteins were expressed from the pYY1 expression construct containing full-length, MTS, or MTS WHEP *GARS*, or no insert (empty); these constructs were a gift from Chin-I Chien and Chien-Chia Wang (National Central University, Taiwan) (Chien et al., 2014). We made pYY1 Gateway-compatible by digesting the empty pYY1 plasmid with *Spe*I (New England Biolabs), blunt-cloning in reading frame cassette A (Invitrogen), and subsequent transformation into ccdB resistant *E. coli* (Invitrogen) and purification of plasmid DNA. Sanger sequencing confirmed proper cassette orientation downstream of the *ADHI* promoter. To generate human *GARS* expression constructs for yeast experiments, the full-length, MTS, and MTS WHEP *GARS* open-reading frames were amplified from the initial expression constructs with primers bearing Gateway flanking sequences. The resulting PCR products were gel-purified and BP-cloned into the pDONR221 entry vector (ThermoFisher Scientific). Sanger

sequencing confirmed specificity and lack of PCR-induced errors. The p.Arg310Gln *GARS* variant was generated using the QuickChange II XL Site-Directed Mutagenesis Kit, a sequence validated wild-type full-length, MTS, or MTS WHEP *GARS* pDONR221 template, and variant-specific primers. The reaction was transformed into *E. coli*, plasmid DNA was purified from the individual colonies and then subjected to Sanger sequencing to confirm the presence of the variant and the absence of PCR-induced errors. A sequence-validated pDONR221 construct for wild-type or mutant full-length, MTS, or

MTS WHEP *GARS* was LR-cloned into the Gateway compatible pYY1 construct. The resulting reactions were transformed into *E. coli*, purified, and digested with *Bsr*G1 (New England Biolabs) to confirm the presence of the respective human *GARS* open-reading frame.

Aminoacylation assays

Wild-type and p.Arg310Gln *GARS* were expressed in *E. coli* with a C-terminal His tag and purified with nickel affinity resins (Novagen). The T7 transcript of human tRNA^{Gly}/UCU (UCU, anticodon) was prepared and purified as previously described (Hou et al., 1993), heat denatured at 85°C for 3 min, and annealed at 37°C for 20 min before use. Steady-state aminoacylation assays were monitored at 37°C in 50 mM HEPES (pH 7.5), 20 mM KCl, 10 mM MgCl₂, 4 mM DTT, 2 mM ATP, and 50 mM 3H-glycine (Perkin Elmer) at a specific activity of 16,500 dpm/pmole. The reaction was initiated by mixing *GARS* enzyme (20–600 nM) with varying concentrations of tRNA (0.3–20 μM). Aliquots of a reaction mixture were spotted on filter paper, quenched by 5% trichloroacetic acid, washed, dried, and measured for radioactivity using a liquid scintillation counter (LS6000SC; Beckman Coulter Inc.). The amount of radioactivity retained on filter pads was corrected for quenching effects to determine the amount of synthesis of Gly-tRNA^{Gly}. Steady-state kinetics was determined by fitting the initial rate of aminoacylation as a function of tRNA concentration to the Michaelis-Menten equation (Schreier and Schimmel, 1972).

Yeast complementation assays

Yeast complementation assays were carried out using the haploid *S. cerevisiae* strain disrupted for the endogenous *GRS1* and maintained viable via pRS316 bearing wild-type *GRS1* (Turner et al., 2000). To assess the ability of wild-type and mutant human *GARS* alleles to support cellular growth, the haploid yeast strain was transformed with wild-type full-length, wild-type MTS, or wild-type MTS WHEP *GARS*, the corresponding p.Arg310Gln *GARS* expression constructs, or empty pYY1 (*i.e.*, bearing no *GARS* insert) (Chien et al., 2014). Transformed yeast cells were selected for the presence of pYY1 by growth on solid media lacking leucine (pYY1 harbors the *LEU2* gene) and uracil (pRS316 harbors the *URA3* gene). Colonies were grown to saturation in 2 mL liquid medium lacking leucine and uracil (-leu-ura) at 30°C and shaking at 275 rpm for 48 hours. Each 2 mL saturated culture was spun down at 1,000 rpm and re-suspended in 100 μL UltraPure Rnase/DNase-free water. Undiluted cultures and dilutions of 1:10, 1:100, and 1:1,000 were spotted on 0.1% 5-FOA complete solid medium (Teknova, Hollister CA) to select for cells that spontaneously lost the *URA3*-bearing maintenance vector (Boeke et al., 1984). Yeast viability was visually assessed after 4 days of incubation at 30°C. Two colonies per transformation were assayed and each transformation was repeated twice.

RESULTS

Clinical and genetic analysis of patient UDP5316

A simplex pedigree was presented to the NIH Undiagnosed Diseases Program. The proband is a seven-year-old Caucasian female of non-consanguineous German and Polish ancestry with extreme growth retardation and multiple organ involvement as described below. She was a 1.52 kg infant born at 36 weeks gestation to a 27-year-old G1P0 mother by scheduled Caesarian section due to severe intrauterine growth retardation beginning at 29 weeks. There were no maternal exposures and maternal weight gain was only 5 pounds. APGAR scores were 4 and 9 at 1 and 4 minutes, respectively. Length, weight, and head circumference were all 50th percentile for 31 weeks gestation. She remained in the NICU for 2 weeks for poor weight gain.

TORCH titers (Group B streptococci, toxoplasma, CMV, HSV II) were negative. HSV I IgG was reported positive (greater than 5), indicating a previous immunological exposure but the patient did not show clinical signs of active infection and did not receive treatment; this might be due to an outbreak of cold sores as reported by the proband's mother early in pregnancy. Hepatitis B, hepatitis C, Rubella, HIV, Herpes, and standard STD panel were negative. Ophthalmic exam was normal. An echocardiogram revealed peripheral pulmonic stenosis.

Despite adequate calories the child failed to thrive. X-rays at 7 months of age showed cephalofacial disproportion with a large calvaria, numerous wormian bones, and low-normal bone mineralization. Skull X-ray at 2 years, 9 months of age no longer showed the wormian bones, but the rest of the findings remained the same (Supp. Figure S1). Brain MRI at 29 months showed moderate-to-severe thinning of the corpus callosum, mild atrophy of the cerebellar vermis, and a small brain stem (Fig. 1A). There was decreased cerebral white matter volume consistent with delayed myelination (also observed at 11 months of age; data not shown), and mildly enlarged ventricles. Cervical X-ray revealed that C5 through C7 were fused (Fig. 1B). Cardiac evaluation at 4 years identified a moderately sized atrial septal defect and pulmonic stenosis. A sleep study demonstrated severe central and obstructive apnea. Recurrent ear and upper respiratory infections prompted myringotomy tube placement and prophylactic antibiotic treatments. She continues to suffer from atopic dermatitis and recurrent rhinitis. Developmentally, the child rolled at 4 months, sat at 16 months, commando crawled at 10 months, cruised at 22 months, and walked at 6 years. Fine motor skills include feeding herself with a pincer grasp at 5 years and holding a pencil at 5 years. Her verbal skills include 20–25 single words with poor intelligibility.

On initial NIH evaluation at 2 years 9 months her weight was 7.6 kgs, height was 72 cm, and head circumference was 43 cm. These measures are all below the 5th percentile for 33 months of age. The child was microcephalic with a patent anterior fontanelle and sparse, thin scalp hair. Facial features included a triangular face with broad forehead, prominent epicanthal folds, hypotelorism, smooth philtrum, and a high-arched palate. She was non-ambulatory and displayed upper motor neuron signs with hyperreflexia and spasticity of both upper and lower extremities but normal range of motion and hypermobility of her

ankles. She did not have any signs of a lower motor neuron disorder or neuropathy and her sensation to temperature, light touch, and vibration were all normal.

Dilated ophthalmologic evaluation revealed a normal macula and vessels but peripheral retinal changes including atrophy and depigmentation. Auditory evaluation showed bilateral sensorineural hearing loss.

To identify candidate variants for the unexplained phenotype, whole-exome sequencing analysis was performed on genomic DNA isolated from the patient (UDP5316), her unaffected mother (UDP6340), and her unaffected father (UDP6341) (UDP; Fig. 2A). Using a Boolean sort with parents and proband as heterozygous in VarSifter, a mean allele frequency of <0.02 (1,000 genomes), and an allele frequency of 0 in the NIH-UDP cohort (Bentley et al., 2008; Gnirke et al., 2009; Teer et al., 2010; Gahl and Tifft, 2011; Gahl et al., 2012; Markello et al., 2012; Teer et al., 2012), we identified two variants in the gene encoding hexokinase 3 (*HK3*) and two variants in the gene encoding glycyl-tRNA synthetase (*GARS*). The *HK3* variants were excluded from further analyses because one variant (c.1733A>G, NM_002115.2; rs61749651) is present in the exome aggregate (ExAC)/genome aggregate (gnomAD) database (Lek et al., 2016) at a relatively high frequency (3,862 alleles in 276,696 chromosomes including 54 homozygous genotypes). The *GARS* variants (NM_002047.3) include : (1) c.246_249del, which is predicted to cause an early frame-shift variant p.Glu83Ilefs*6; and (2) c.929G>A, which is predicted to cause a missense variant p.Arg310Gln (Table 1). The unaffected mother carries p.Glu83Ilefs*6 in the heterozygous state, the unaffected father carries p.Arg310Gln in the heterozygous state, and the affected proband is compound heterozygous for both *GARS* variants (Fig. 2A and 2B). Neither variant is present in the ExAC/gnomAD database (Table 1) (Lek et al., 2016). Modeling each of the identified *GARS* variants on the primary structure of the protein revealed that p.Glu83Ilefs*6 is predicted to ablate all key functional domains of the enzyme (both catalytic domains and the tRNA binding domain) and that p.Arg310Gln affects a residue in the catalytic core of the enzyme (Fig. 2C). Multiple-species conservation analysis revealed that p.Arg310Gln affects a residue that is conserved among diverse species including human, mouse, zebrafish, and worm (Fig. 2D).

p.Glu83Ilefs*6 GARS reduces expression of the full-length GARS protein

Because p.Glu83Ilefs*6 *GARS* encodes a premature stop codon, the variant is predicted to ablate the expression of full-length GARS, which would result in a 50% decrease in full-length GARS protein levels in patient cells. To test this, we performed western blot analysis using whole-cell lysates from fibroblasts isolated from patient UDP5316 and from an unaffected control (*i.e.*, a patient negative for *GARS* variants). Protein samples were electrophoresed, transferred onto a PVDF membrane, and incubated with an anti-GARS antibody (Antonellis et al., 2006). Our results revealed a ~50% reduction in full-length GARS protein levels in the patient fibroblast cells compared to the control cell line (Fig. 2A); a similar assessment of three additional control fibroblast samples confirmed these findings (Supp. Figure S2). To confirm the sensitivity of our western blot analysis, we analyzed 20µg, 10µg, and 5µg of total protein from the control cell lysate with the same antibody and were able to detect a 50% reduction in protein levels (Fig. 3A). We therefore

conclude that p.Gly83IlefsX6 *GARS* ablates the expression of full-length *GARS* and posit that the remaining protein represents translation from the p.Arg310Gln *GARS* allele.

The p.Arg310Gln *GARS* variant reduces enzyme activity

The primary function of *GARS* is to charge tRNA^{Gly} molecules with glycine in a two-step aminoacylation reaction: (i) binding and activation of the amino acid with ATP and (ii) conjugation of the activated amino acid to the 3'-end of the appropriate tRNA (Delarue, 1995). The aminoacylation assay evaluates the completion of both steps and has been used to establish that CMT2D-associated variants disrupt *GARS* enzymatic activity (Nangle et al., 2007; Griffin et al., 2014). We assessed recombinant human *GARS* proteins (wild-type and p.Arg310Gln) for the ability to charge human cytoplasmic tRNA^{Gly} with tritium-labeled glycine as previously described (Griffin et al., 2014). Analysis of the initial rate of aminoacylation as a function of the tRNA substrate concentration showed that p.Arg310Gln *GARS* demonstrates less than 1% aminoacylation activity compared to wild-type *GARS* (Fig. 3B and Table 2) indicating that it is a hypomorphic allele.

The p.Arg310Gln *GARS* variant does not support yeast cell growth in complementation assays

Yeast complementation assays have been employed to reveal loss-of-function characteristics of CMT2D-associated *GARS* variants (Antonellis et al., 2006; Griffin et al., 2014). While previous efforts employed the yeast ortholog of *GARS* (*GRS1*) to assess human variants (Turner et al., 2000; Antonellis et al., 2006; Griffin et al., 2014), a recent study showed that three engineered isoforms of the human *GARS* protein were able to rescue deletion of *GRS1*: (1) full-length *GARS* allowed minimal cell growth; (2) *GARS* with the mitochondrial targeting sequence deleted (ΔMTS) allowed intermediate cell growth; and (3) *GARS* with both the MTS and WHEP domain deleted (ΔMTS ΔWHEP) allowed robust cell growth (Chien et al., 2014) [the function of the WHEP domain has not been defined but it is not essential for enzyme activity (Chang et al., 2016)]. We therefore evaluated the effect of the p.Arg310Gln *GARS* variant in all three of the above *GARS* isoforms. Briefly, the wild-type or p.Arg310Gln *GARS* open-reading frames (full-length, ΔMTS, or ΔMTS ΔWHEP) were cloned downstream of the yeast *ADHI* promoter (Chien et al., 2014) and yeast complementation assays were performed using a haploid yeast strain deleted for the endogenous *GRS1* locus (Δ*GRS1*); this strain carries wild-type *GRS1* on a *URA3*-bearing maintenance vector to maintain viability (Turner et al., 2000). Wild-type or mutant *GARS* expression constructs, or one with no *GARS* insert ('Empty' in Fig. 3C), were introduced into the above strain and growth was subsequently evaluated on medium containing 0.1% 5-FOA, which selects for the spontaneous loss of the maintenance vector (Boeke et al., 1984). All of the wild-type human *GARS* expression constructs supported yeast growth, while the empty plasmid did not (Fig. 3C), consistent with human *GARS* supporting loss of the endogenous *GRS1* locus and with *GRS1* being an essential gene, respectively. In contrast, none of the p.Arg310Gln *GARS* expression constructs supported yeast cell growth, consistent with this being a loss-of-function allele (Fig. 3C). Combined, our functional studies indicate that p.Gly83IlefsX6 *GARS* represents a null allele and that p.Arg310Gln *GARS* represents a hypomorphic allele.

DISCUSSION

Twenty eight ARS loci encoding mitochondrial, cytoplasmic, and bi-functional ARS enzymes have been implicated in myriad recessive human diseases (Oprescu et al., 2017). *GARS* variants cause autosomal dominant, axonal Charcot-Marie-Tooth disease (CMT2D) (Antonellis et al., 2003) but have not been convincingly implicated in recessive phenotypes. Here we present clinical, genetic, and functional data that implicate *GARS* variants in a severe, multi-system, developmental phenotype. Our functional studies indicate that p.Gly83IlefsX6 *GARS* ablates the expression of full-length *GARS* and that p.Arg310Gln *GARS* represents a severely hypomorphic allele. It is important to note that aminoacylation and yeast complementation assays were previously employed to implicate loss-of-function variants at other ARS loci in recessive diseases similar to the phenotype described here (please see below): aminoacylation assays have been used to study disease-associated variants at 15 ARS loci and yeast complementation assays have been used to study disease-associated variants at eight ARS loci (Oprescu et al., 2017). Therefore, our informative and relevant functional analyses support the pathogenicity of p.Gly83IlefsX6 and p.Arg310Gln *GARS* in the phenotype reported here.

Careful clinical comparisons between our patient and previously reported patients with ARS-associated recessive phenotypes (Oprescu et al., 2017) reveals remarkable overlap, further supporting the pathogenicity of the *GARS* variants reported here. For example, ARS genes have been associated with the following recessive phenotypes; (i) growth retardation in patients with *AARS* (MIM# 601065), *IARS* (MIM# 600709), *MARS* (MIM# 156560), *MARS2* (MIM# 609728), *QARS* (MIM# 603727), *VAR2* (MIM# 612802), and *YARS* (MIM# 603623) variants; (ii) microcephaly in patients with *AARS*, *IARS*, *KARS* (MIM# 601421), *NARS2* (MIM# 612803), *PARS2* (MIM# 612036), *QARS*, *VAR2* (MIM# 192150), and *VAR2* variants; (iii) thinning of the corpus callosum in patients with *AARS2* (MIM# 612035), *CARS2* (MIM# 612800), *EARS2* (MIM# 612799), *FARS2* (MIM# 611592), *KARS*, *QARS*, *TARS2* (MIM# 612805), *VAR2*, *YARS*, and *YARS2* (MIM# 610957) variants; (iv) decreased white matter in patients with *KARS* and *QARS* variants; (v) brain stem involvement in patients with *DARS2* (MIM# 610956), *QARS*, and *RARS2* (MIM# 611524) variants; (vi) spasticity in patients with *AARS*, *DARS*, *FARS2*, *IARS*, *MARS2*, and *RARS* (MIM# 107820) variants; and (vii) sensorineural hearing loss in patients with *CARS2*, *HARS2* (MIM# 600783), *IARS*, *IARS2* (MIM# 612801), *KARS*, *LARS2* (MIM# 604544), and *MARS2* variants.

The recessive disorders caused by variants in the three bi-functional ARSs appear to share more clinical phenotypes compared to all ARS-associated disorders as a whole. Our patient shares many features with patients who are compound heterozygous for glutaminyl-tRNA synthetase (*QARS*) (Zhang et al., 2014) or lysyl-tRNA synthetase (*KARS*) variants (McLaughlin et al., 2010; Santos-Cortez et al., 2013; McMillan et al., 2015). Specifically, our patient shares growth retardation, microcephaly, thinning of the corpus callosum, decreased white matter, and brain stem involvement (all noted above), as well as large calvaria, cerebellar vermis atrophy, dysmorphic features, prominent epicanthal folds, hypotelorism, high-arched palate, delayed motor milestones, apnea, and sparse thin scalp hair with patients carrying loss-of-function *QARS* variants. Our patient also shares

microcephaly, thinning of the corpus callosum, decreased white matter, and sensorineural hearing loss (all noted above), as well as dysmorphic features and delayed motor development with patients carrying loss-of-function *KARS* variants. These observations are significant since *GARS*, *QARS*, and *KARS* compose the three bi-functional ARSs that charge tRNA in the cytoplasm and mitochondria (Antonellis and Green, 2008). In summary, the clinical features of our patient compared to other patients with ARS variants and our functional studies showing that p.Gly83IlefsX6 and p.Arg310Gln dramatically impair *GARS* function both support the conclusion that compound heterozygosity for loss-of-function *GARS* variants results in the severe, multi-system, developmental phenotype reported here.

Loss-of-function missense variants in *GARS* have been associated with CMT2D, which is characterized by distal muscle weakness and sensory loss that is predominant in the upper extremities (Antonellis et al., 2003; Sivakumar et al., 2005). Interestingly, neither parent of the affected proband currently displays signs of CMT2D; EMG and nerve conduction studies performed on both parents were unremarkable at ages 30 (mother) and 32 (father); these ages are well-beyond the average age of onset for CMT2D, which is typically in the second decade of life (Sivakumar et al., 2005). With regard to the mother who carries the null allele (p.Gly83IlefsX6), this is perhaps not surprising since haploinsufficiency is not a likely mechanism of *GARS*-associated CMT2D; mice heterozygous for a null allele have no detectable phenotype while mice heterozygous for a missense variant present with a dominant neuropathy (Seburn et al., 2006; Motley et al., 2011). In contrast, p.Arg310Gln *GARS* shows features of CMT2D-associated variants (Griffin et al., 2014); it is a missense variant in the catalytic domain that affects tRNA charging capacity. Two possible explanations for this discrepancy are the reduced penetrance of *GARS* variants as seen for p.Glu71Gly and p.Leu129Pro *GARS* (Sivakumar et al., 2005) and the poorly defined mechanism of CMT2D (*i.e.*, p.Arg310Gln *GARS* may be a loss-of-function missense variant that is not dominantly toxic to peripheral nerve axons). Addressing this discrepancy will require animal models and molecular studies to determine if, for example, p.Arg310Gln *GARS* inappropriately binds neuropilin-1, which has been observed for certain CMT2D-causing variants (He et al., 2015).

In conclusion, we present clinical, genetic, and functional data that associate *GARS* variants with a severe, multi-system, developmental phenotype. This report exemplifies the growing number of ARS loci and alleles implicated in recessive human diseases (Oprescu et al., 2017), expands the phenotypic heterogeneity associated with *GARS* variants, and underscores the importance of employing careful clinical comparisons and informative functional studies to support the pathogenicity of newly identified ARS variants.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors are indebted to the patient and their family for participating in this study. We would also like to thank Chin-I Chien and Chien-Chia Wang (National Central University, Taiwan) for the pYY1 expression construct and Laurie Griffin for assistance with developing GARS expression constructs.

Contract grant sponsors: This work was supported by the National Institute of General Medical Sciences (GM110184 and GM118647 to A.A.; GM108972 and GM114343 to Y.M.H). This study was also supported in part by the Intramural Research Program of the National Human Genome Research Institute and the NIH Common Fund, Office of the Director.

References

- Antonellis A, Ellsworth RE, Sambuughin N, Puls I, Abel A, Lee-Lin S-Q, Jordanova A, Kremensky I, Christodoulou K, Middleton LT, Sivakumar K, Ionasescu V, Funalot B, Vance JM, Goldfarb LG, Fischbeck KH, Green ED. Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. 2003; 72:1293–1299.
- Antonellis A, Green ED. The role of aminoacyl-tRNA synthetases in genetic diseases. Annual review of genomics and human genetics. 2008; 9:87–107.
- Antonellis A, Lee-Lin S-Q, Wasterlain A, Leo P, Quezado M, Goldfarb LG, Myung K, Burgess S, Fischbeck KH, Green ED. Functional analyses of glycyl-tRNA synthetase mutations suggest a key role for tRNA-charging enzymes in peripheral axons. J Neurosci. 2006; 26:10397–10406. [PubMed: 17035524]
- Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, Hall KP, Evers DJ, Barnes CL, Bignell HR, Boutell JM, Bryant J, Carter RJ, Keira Cheetham R, Cox AJ, Ellis DJ, Flatbush MR, Gormley NA, Humphray SJ, Irving LJ, Karbelashvili MS, Kirk SM, Li H, Liu X, Maisinger KS, Murray LJ, Obradovic B, Ost T, Parkinson ML, Pratt MR, Rasoloniato IM, Reed MT, Rigatti R, Rodighiero C, Ross MT, Sabot A, Sankar SV, Scally A, Schroth GP, Smith ME, Smith VP, Spiridou A, Torrance PE, Tzonev SS, Vermaas EH, Walter K, Wu X, Zhang L, Alam MD, Anastasi C, Aniebo IC, Bailey DM, Bancarz IR, Banerjee S, Barbour SG, Baybayan PA, Benoit VA, Benson KF, Bevis C, Black PJ, Boodhun A, Brennan JS, Bridgham JA, Brown RC, Brown AA, Buermann DH, Bundu AA, Burrows JC, Carter NP, Castillo N, Chiara E, Catenazzi M, Chang S, Neil Cooley R, Crake NR, Dada OO, Diakoumakos KD, Dominguez-Fernandez B, Earnshaw DJ, Egbujor UC, Elmore DW, Etchin SS, Ewan MR, Fedurco M, Fraser LJ, Fuentes Fajardo KV, Scott Furey W, George D, Gietzen KJ, Goddard CP, Golda GS, Granieri PA, Green DE, Gustafson DL, Hansen NF, Harnish K, Haudenschild CD, Heyer NI, Hims MM, Ho JT, Horgan AM, Hoschler K, Hurwitz S, Ivanov DV, Johnson MQ, James T, Huw Jones TA, Kang GD, Kerelska TH, Kersey AD, Khrebtukova I, Kindwall AP, Kingsbury Z, Kokko-Gonzales PI, Kumar A, Laurent MA, Lawley CT, Lee SE, Lee X, Liao AK, Loch JA, Lok M, Luo S, Mammen RM, Martin JW, McCauley PG, McNitt P, Mehta P, Moon KW, Mullens JW, Newington T, Ning Z, Ling NgB, Novo SM, O'Neill MJ, Osborne MA, Osnowski A, Ostadan O, Paraschos LL, Pickering L, Pike AC, Pike AC, Chris Pinkard D, Pliskin DP, Podhasky J, Quijano VJ, Raczy C, Rae VH, Rawlings SR, Chiva Rodriguez A, Roe PM, Rogers J, Rogert Bacigalupo MC, Romanov N, Romieu A, Roth RK, Rourke NJ, Ruediger ST, Rusman E, Sanches-Kuiper RM, Schenker MR, Seoane JM, Shaw RJ, Shiver MK, Short SW, Sizto NL, Sluis JP, Smith MA, Ernest Sohna Sohna J, Spence EJ, Stevens K, Sutton N, Szajkowski L, Tregidgo CL, Turcatti G, Vandevondele S, Verhovsky Y, Virk SM, Wakelin S, Walcott GC, Wang J, Worsley GJ, Yan J, Yau L, Zuerlein M, Rogers J, Mullikin JC, Hurles ME, McCooke NJ, West JS, Oaks FL, Lundberg PL, Klenerman D, Durbin R, Smith AJ. Accurate whole human genome sequencing using reversible terminator chemistry. Nature. 2008; 456:53–59. [PubMed: 18987734]
- Boeke JD, LaCrute F, Fink GR. A positive selection for mutants lacking orotidine-5'-phosphate decarboxylase activity in yeast: 5-fluoro-orotic acid resistance. Mol Gen Genet. 1984; 197:345–346. [PubMed: 6394957]
- Chang C-Y, Chien C-I, Chang C-P, Lin B-C, Wang C-C. A WHEP Domain Regulates the Dynamic Structure and Activity of *Caenorhabditis elegans* Glycyl-tRNA Synthetase. J Biol Chem. 2016; 291:16567–16575. [PubMed: 27298321]

- Chien C-I, Chen Y-W, Wu Y-H, Chang C-Y, Wang T-L, Wang C-C. Functional substitution of a eukaryotic glycyl-tRNA synthetase with an evolutionarily unrelated bacterial cognate enzyme. *PLoS ONE*. 2014; 9:e94659. [PubMed: 24743154]
- Chihara T, Luginbuhl D, Luo L. Cytoplasmic and mitochondrial protein translation in axonal and dendritic terminal arborization. *Nat Neurosci*. 2007; 10:828–837. [PubMed: 17529987]
- Delarue M. Aminoacyl-tRNA synthetases. *Curr Opin Struct Biol*. 1995; 5:48–55. [PubMed: 7773747]
- Gahl WA, Markello TC, Toro C, Fajardo KF, Sincan M, Gill F, Carlson-Donohoe H, Gropman A, Pierson TM, Golas G, Wolfe L, Groden C, Godfrey R, Nehrebecky M, Wahl C, Landis DM, Yang S, Madeo A, Mullikin JC, Boerkoel CF, Tift CJ, Adams D. The National Institutes of Health Undiagnosed Diseases Program: insights into rare diseases. *Genet Med*. 2012; 14:51–59. [PubMed: 22237431]
- Gahl WA, Tift CJ. The NIH Undiagnosed Diseases Program: lessons learned. *JAMA*. 2011; 305:1904–1905. [PubMed: 21558523]
- Gnirke A, Melnikov A, Maguire J, Rogov P, LeProust EM, Brockman W, Fennell T, Giannoukos G, Fisher S, Russ C, Gabriel S, Jaffe DB, Lander ES, Nusbaum C. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. *Nat Biotechnol*. 2009; 27:182–189. [PubMed: 19182786]
- Griffin LB, Sakaguchi R, McGuigan D, Gonzalez MA, Searby C, Züchner S, Hou Y-M, Antonellis A. Impaired Function is a Common Feature of Neuropathy-Associated Glycyl-tRNA Synthetase Mutations. *Hum Mutat*. 2014; 35:1363–1371. [PubMed: 25168514]
- He W, Bai G, Zhou H, Wei N, White NM, Lauer J, Liu H, Shi Y, Dumitru CD, Lettieri K, Shubayev V, Jordanova A, Guergueltcheva V, Griffin PR, Burgess RW, Pfaff SL, Yang XL. CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase. *Nature*. 2015; 526:710–714. [PubMed: 26503042]
- Hou YM, Westhof E, Giegé R. An unusual RNA tertiary interaction has a role for the specific aminoacylation of a transfer RNA. *Proc Natl Acad Sci USA*. 1993; 90:6776–6780. [PubMed: 8341698]
- Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, Tukiainen T, Birnbaum DP, Kosmicki JA, Duncan LE, Estrada K, Zhao F, Zou J, Pierce-Hoffman E, Berghout J, Cooper DN, Deflaux N, DePristo M, Do R, Flannick J, Fromer M, Gauthier L, Goldstein J, Gupta N, Howrigan D, Kiezun A, Kurki MI, Moonshine AL, Natarajan P, Orozco L, Peloso GM, Poplin R, Rivas MA, Ruano-Rubio V, Rose SA, Ruderfer DM, Shakir K, Stenson PD, Stevens C, Thomas BP, Tiao G, Tusie-Luna MT, Weisburd B, Won HH, Yu D, Altshuler DM, Ardissino D, Boehnke M, Danesh J, Donnelly S, Elosua R, Florez JC, Gabriel SB, Getz G, Glatt SJ, Hultman CM, Kathiresan S, Laakso M, McCarroll S, McCarthy MI, McGovern D, McPherson R, Neale BM, Palotie A, Purcell SM, Saleheen D, Scharf JM, Sklar P, Sullivan PF, Tuomilehto J, Tsuang MT, Watkins HC, Wilson JG, Daly MJ, MacArthur DG. Analysis of protein-coding genetic variation in 60,706 humans. *Nature*. 2016; 536:285–291. [PubMed: 27535533]
- Markello TC, Han T, Carlson-Donohoe H, Ahaghotu C, Harper U, Jones M, Chandrasekharappa S, Anikster Y, Adams DR, Gahl WA, Boerkoel CF. NISC Comparative Sequencing Program. Recombination mapping using Boolean logic and high-density SNP genotyping for exome sequence filtering. *Mol Genet Metab*. 2012; 105:382–389. [PubMed: 22264778]
- McLaughlin HM, Sakaguchi R, Liu C, Igarashi T, Pehlivan D, Chu K, Iyer R, Cruz P, Cherukuri PF, Hansen NF, Mullikin JC, Biesecker LG, Wilson TE, Ionasescu V, Nicholson G, Searby C, Talbot K, Vance JM, Züchner S, Szigeti K, Lupski JR, Hou YM, Green ED, Antonellis A. NISC Comparative Sequencing Program. Compound heterozygosity for loss-of-function lysyl-tRNA synthetase mutations in a patient with peripheral neuropathy. 2010; 87:560–566.
- McMillan HJ, Humphreys P, Smith A, Schwartzentruber J, Chakraborty P, Bulman DE, Beaulieu CL, Majewski J, Boycott KM, Geraghty MT. FORGE Canada Consortium. Congenital Visual Impairment and Progressive Microcephaly Due to Lysyl-Transfer Ribonucleic Acid (RNA) Synthetase (KARS) Mutations. *Journal of Child Neurology*. 2015; 30:1037–1043. [PubMed: 25330800]
- McMillan HJ, Schwartzentruber J, Smith A, Lee S, Chakraborty P, Bulman DE, Beaulieu CL, Majewski J, Boycott KM, Geraghty MT. Compound heterozygous mutations in glycyl-tRNA

- synthetase are a proposed cause of systemic mitochondrial disease. *BMC Med Genet.* 2014; 15:36. [PubMed: 24669931]
- Motley WW, Seburn KL, Nawaz MH, Miers KE, Cheng J, Antonellis A, Green ED, Talbot K, Yang X-L, Fischbeck KH, Burgess RW. Charcot-Marie-Tooth-linked mutant GARS is toxic to peripheral neurons independent of wild-type GARS levels. 2011; 7:e1002399.
- Nangle LA, Zhang W, Xie W, Yang X-L, Schimmel P. Charcot-Marie-Tooth disease-associated mutant tRNA synthetases linked to altered dimer interface and neurite distribution defect. *Proc Natl Acad Sci USA.* 2007; 104:11239–11244. [PubMed: 17595294]
- Oprescu SN, Griffin LB, Beg AA, Antonellis A. Predicting the pathogenicity of aminoacyl-tRNA synthetase mutations. *Methods.* 2017; 113:139–151. [PubMed: 27876679]
- Santos-Cortez RL, Lee K, Azeem Z, Antonellis PJ, Pollock LM, Khan S, Irfanullah, Andrade-Elizondo PB, Chiu I, Adams MD, Basit S, Smith JD, Nickerson DA, McDermott BM Jr, Ahmad W, Leal SM. University of Washington Center for Mendelian Genomics. Mutations in KARS, encoding lysyl-tRNA synthetase, cause autosomal-recessive nonsyndromic hearing impairment DFNB89. *Am J Hum Genet.* 2013; 93:132–140. [PubMed: 23768514]
- Schreier AA, Schimmel PR. Transfer ribonucleic acid synthetase catalyzed deacylation of aminoacyl transfer ribonucleic acid in the absence of adenosine monophosphate and pyrophosphate. *Biochemistry.* 1972; 11:1582–1589. [PubMed: 4337554]
- Seburn KL, Nangle LA, Cox GA, Schimmel P, Burgess RW. An active dominant mutation of glycyl-tRNA synthetase causes neuropathy in a Charcot-Marie-Tooth 2D mouse model. *Neuron.* 2006; 51:715–726. [PubMed: 16982418]
- Sivakumar K, Kyriakides T, Puls I, Nicholson GA, Funalot B, Antonellis A, Sambuughin N, Christodoulou K, Beggs JL, Zamba-Papanicolaou E, Ionasescu V, Dalakas MC, Green ED, Fischbeck KH, Goldfarb LG. Phenotypic spectrum of disorders associated with glycyl-tRNA synthetase mutations. *Brain.* 2005; 128:2304–2314. [PubMed: 16014653]
- Teer JK, Bonnycastle LL, Chines PS, Hansen NF, Aoyama N, Swift AJ, Abaan HO, Albert TJ, Margulies EH, Green ED, Collins FS, Mullikin JC, Biesecker LG. NISC Comparative Sequencing Program. Systematic comparison of three genomic enrichment methods for massively parallel DNA sequencing. *Genome Res.* 2010; 20:1420–1431. [PubMed: 20810667]
- Teer JK, Green ED, Mullikin JC, Biesecker LG. VarSifter: visualizing and analyzing exome-scale sequence variation data on a desktop computer. *Bioinformatics.* 2012; 28:599–600. [PubMed: 22210868]
- Turner RJ, Lovato M, Schimmel P. One of two genes encoding glycyl-tRNA synthetase in *Saccharomyces cerevisiae* provides mitochondrial and cytoplasmic functions. *J Biol Chem.* 2000; 275:27681–27688. [PubMed: 10874035]
- Zhang X, Ling J, Barcia G, Jing L, Wu J, Barry BJ, Mochida GH, Hill RS, Weimer JM, Stein Q, Poduri A, Partlow JN, Ville D, Dulac O, Yu TW, Lam AT, Servattalab S, Rodriguez J, Boddaert N, Munnich A, Colleaux L, Zon LI, Söll D, Walsh CA, Nabbout R. Mutations in QARS, encoding glutaminyl-tRNA synthetase, cause progressive microcephaly, cerebral-cerebellar atrophy, and intractable seizures. 2014; 94:547–558.

Figure 1.

Clinical features of patient UDP5316. **(A)** Representative MRI images for the proband at 29 months of age. Cerebral cortex appeared normal, but there was decreased cerebral white matter volume and delayed myelination (shown in 1, coronal image, T1-weighted), moderate-to-severe thinning of the corpus callosum, mild atrophy of the cerebellar vermis, small brain stem (shown in 2, sagittal image, T1-weighted), and mildly enlarged ventricles (axial images; 3, FLAIR; 4, T2-weighted). **(B)** Cervical spine X-ray shows fusion of C5–C7 vertebra. **(C–E)** Growth curves of the patient plotted in comparison with normal children 0–36 months of age; weight **(C)**, height **(D)**, and head circumference **(E)**.

Figure 2.

Identification of *GARS* variants in patient UDP5316. **(A)** The simplex pedigree is shown with squares representing males, circles representing females, and diagonal lines representing deceased individuals. Sample numbers and genotypes are indicated under each symbol for the mother, father, and proband (filled circle). The proband is the only affected individual in the pedigree. **(B)** Representative sequence chromatograms are shown for the identified variants (protein and cDNA annotations are provided at the top) in the indicated individuals (indicated along the left side). Arrows indicate the position of each variant. **(C)** *GARS* functional domains are indicated in red (catalytic domain) and green (anti-codon binding domain), and the position of each variant is shown across the top. Numbers along the bottom indicate amino acid positions. **(D)** The position of the p.Arg310Gln variant is shown along with flanking amino acid residues for multiple, evolutionarily diverse species. The position of the affected residue is shown in red for each species.

Figure 3.

The *GARS* variants identified in patient UDP5316 reduce gene function. **(A)** Western blot analyses were performed with total protein lysates from fibroblast cell lines from unaffected (Control) and affected (UDP5316) patients using an anti-GARS or anti-actin antibody, as indicated. Sample names are across the top and sizes (kDa) are indicated at the left. **(B)** Initial aminoacylation rates (pmole/min) of wild-type (black circles and line) and p.Arg310Gln *GARS* (orange circles and line) were plotted against tRNA concentrations and fit to the Michaelis-Menten equation. Error bars indicate standard deviations. **(C)** Representative cultures of the indicated yeast strains were plated on solid growth medium containing 5-FOA. Each strain was previously transfected with a vector containing no insert (Empty pYY1), or containing either wild-type (Wt) or mutant (p.Arg310Gln) *GARS* in open-reading frames to express full-length (FL) protein, a protein with the mitochondrial targeting sequence deleted (), or a protein with the mitochondrial targeting sequence and the WHEP domain deleted (). Before inoculating on medium containing 5-FOA, each strain was diluted 1:10, 1:100, or 1:1,000 in water. Please note the minimal growth associated with the wild-type FL protein in the undiluted sample, the intermediate growth associated with the wild-type protein in the undiluted and 1:10 diluted samples, and the robust growth associated with wild-type protein in all dilutions.

Table 1*GARS* variants identified in patient UDP5316

Nucleotide change ^a	Amino-acid change ^b	Detection in gnomAD ^c
c.246_249del	p.Glu83Ilefs*6	Not present
c.929G>A	p.Arg310Gln	Not present

^aHuman nucleotide positions correspond to GenBank Accession number NM_002047.3^bHuman amino-acid positions correspond to GenBank Accession number NP_002038.2 ^c<http://gnomad.broadinstitute.org>

Table 2

Kinetic analysis of p.Arg310Gln GARS.

Variant	k_{cat} (s^{-1})	K_{m} (μM)	$k_{\text{cat}}/K_{\text{m}}$ ($\text{s}^{-1} \mu\text{M}^{-1}$)	Ratio
Wild-type	0.049 ± 0.014	0.74 ± 0.30	0.066	1
p.Arg310Gln	$0.00040 \pm 1.0 \times 10^{-4}$	5.5 ± 2.2	7.2×10^{-5}	1/920